Mitral Valve Disease (MVD) is one of the most frequently diagnosed conditions in the breed within the Cavalier King Charles Spaniel. Common indicators include heart murmur detected on examination, coughing especially at night, and exercise intolerance. MVD is the most common heart disease in dogs, characterised by progressive degeneration of the mitral valve leaflets causing regurgitation of blood back into the left atrium. It leads to cardiac enlargement and eventually congestive heart failure. It typically becomes apparent at 5-10 years. In smaller breeds like the Cavalier King Charles Spaniel, early detection and prompt treatment generally lead to better long-term outcomes. This condition has a hereditary component — prospective owners should request documentation of health screening from the breeder. Treatment costs are estimated at £1,500-£5,000/year, making comprehensive pet insurance a practical consideration.
If your Cavalier King Charles Spaniel is showing any of these signs, consult your veterinarian promptly.
The EPIC and PROTECT trials established that Pimobendan delays onset of heart failure in preclinical stages. Once failure develops, diuretics, ACE inhibitors, and Pimobendan are combined.
Estimated Treatment Cost
£1,500-£5,000/year
Costs vary by severity, location, and treatment path. Pet insurance is strongly recommended.
A diet formulation designed to support Cavalier King Charles Spaniels managing Mitral Valve Disease (MVD). Formulated with high-quality protein and easily digestible ingredients.
Check Price on AmazonAs an Amazon Associate we earn from qualifying purchases.
Cavalier King Charles Spaniels with Mitral Valve Disease (MVD) benefit from consistent supplementation. This vet-formulated blend supports overall wellbeing and may complement prescribed treatment.
Check Price on AmazonAs an Amazon Associate we earn from qualifying purchases.
Prevalence and severity can vary significantly between breeds.